Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 16/20 | 0.47 |
| ▸ | JAK2 | O60674 | 15/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371680 | 0.94 | TYK2 (0.42) | TYK2JAK2CCNT1CDK1CDK4 | |
| SCHEMBL2371808 | 0.87 | JAK2 (0.48) | TYK2JAK2CCNT1CDK1CDK4 | |
| SCHEMBL12294327 | 0.85 | JAK2 (0.46) | TYK2JAK2CDK1CDK2CDK9 | |
| SCHEMBL12296293 | 0.81 | JAK2 (0.53) | TYK2JAK2 | |
| SCHEMBL2371645 | 0.80 | PTGES (0.43) | TYK2JAK2 | |
| SCHEMBL12294719 | 0.79 | TYK2 (0.73) | TYK2JAK2CDK2CDK9 | |
| SCHEMBL2372938 | 0.79 | TYK2 (0.59) | TYK2JAK2CDK2CDK9 | |
| SCHEMBL2371829 | 0.79 | TYK2 (0.72) | TYK2JAK2CDK2CDK9 | |
| SCHEMBL2372011 | 0.78 | TYK2 (0.52) | TYK2JAK2 | |
| SCHEMBL2372757 | 0.78 | TYK2 (0.53) | TYK2JAK2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | TYK2 1/4885JAK2 6/4885CCNT1 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.